Showing results (31-40 of 58) with videos related to
Sort By:
Pageof 6
Cardiovascular Endocrinology & Metabolism|February 26, 2021
Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyondSejal Lahoti, Mouhamed Nashawi, Omar Sheikh, et al.Current Atherosclerosis Reports|February 21, 2009
GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effectsMelanie Sulistio, Curtis Carothers, Mandeep Mangat, et al.Diabetes, Obesity & Metabolism|April 8, 2017
Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertensionRobert Chilton, Ilkka Tikkanen, Uwe Hehnke, et al.The American Journal of Cardiology|August 2, 2011
Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitusShailesh Nandish, Jamison Wyatt, Oscar Bailon, et al.Diabetology & Metabolic Syndrome|October 2, 2019
Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseasesAlaaeldin Bashier, Azza Bin Hussain, Elamin Abdelgadir, et al.Current Cardiology Reports|October 30, 2009
Impaired fasting glucose as a treatment target in diabetes managementRene A Oliveros, Adrienne S Zion, Yelena Rosenberg, et al.Current Atherosclerosis Reports|April 29, 2010
A cardiologist's view of hypoglycemiaShailesh Nandish, Jamison Wyatt, Rene Oliveros, et al.Therapeutics and Clinical Risk Management|May 13, 2017
Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozinVani P Sanon, Shalin Patel, Saurabh Sanon, et al.Wiener Klinische Wochenschrift|April 10, 2021
Real-world evidence and product development: Opportunities, challenges and risk mitigationPoobalan Naidoo, Célia Bouharati, Virendra Rambiritch, et al.Cardiovascular Diabetology|June 26, 2019
Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trialOmar Sheikh, Anthony G Vande Hei, Ayman Battisha, et al.Pageof 6